Robeco Institutional Asset Management B.V. Buys Shares of 5,733 PTC Therapeutics, Inc. $PTCT

Robeco Institutional Asset Management B.V. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,733 shares of the biopharmaceutical company's stock, valued at approximately $280,000.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of PTC Therapeutics by 9,393.9% in the 1st quarter. GAMMA Investing LLC now owns 48,514 shares of the biopharmaceutical company's stock worth $2,472,000 after purchasing an additional 48,003 shares during the period. Merit Financial Group LLC acquired a new position in shares of PTC Therapeutics in the 1st quarter worth approximately $205,000. Pallas Capital Advisors LLC acquired a new position in PTC Therapeutics during the 1st quarter valued at approximately $353,000. Wealth Enhancement Advisory Services LLC acquired a new position in PTC Therapeutics during the 1st quarter worth $595,000. Finally, Diversified Trust Co lifted its holdings in shares of PTC Therapeutics by 2.0% in the first quarter. Diversified Trust Co now owns 17,147 shares of the biopharmaceutical company's stock valued at $874,000 after buying an additional 329 shares during the period.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock opened at $64.48 on Thursday. The stock's 50-day simple moving average is $55.17 and its 200 day simple moving average is $50.44. PTC Therapeutics, Inc. has a 52-week low of $35.51 and a 52-week high of $67.40. The stock has a market capitalization of $5.12 billion, a P/E ratio of 9.25 and a beta of 0.55.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.24. The company had revenue of $178.88 million for the quarter, compared to analysts' expectations of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. PTC Therapeutics's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.29) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on PTCT shares. Truist Financial upped their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Royal Bank Of Canada restated an "outperform" rating and set a $63.00 price target (up from $60.00) on shares of PTC Therapeutics in a research report on Friday, August 8th. Wells Fargo & Company reduced their price target on PTC Therapeutics from $79.00 to $73.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 20th. Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a research note on Friday, August 8th. Finally, Wall Street Zen cut PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 9th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $69.00.

Insider Activity

In other news, Director Allan Steven Jacobson sold 12,000 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $65.00, for a total transaction of $780,000.00. Following the completion of the transaction, the director directly owned 17,451 shares in the company, valued at $1,134,315. This trade represents a 40.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Gregory Almstead sold 55,000 shares of PTC Therapeutics stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the transaction, the insider directly owned 100,625 shares in the company, valued at approximately $6,646,281.25. The trade was a 35.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,876 shares of company stock valued at $15,378,035. 5.50% of the stock is currently owned by insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.